• Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • Essential Psychopharmacology
  • Prescriber's Guide
  • Stahl's Illustrated
  • DrugInteraction
  • Teachers Set
 
  • My Bookmarks
  • TOC
  • Donepezil
  • Acamprosate
  • Haloperidol
  • Oxazepam
  • Amisulpride
  • Moclobemide
  • Flumazenil
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Flumazenil

THERAPEUTICS

Brands

  • Romazicon
  • Anexate
  • Lanexat
  • see index for additional brand names

Generic?

  • No

Class

  • Benzodiazepine receptor antagonist

Commonly Prescribed For

  • (bold for FDA approved)
  • Reversal of sedative effects of benzodiazepines after general anesthesia has been induced and/or maintained with benzodiazepines
  • Reversal of sedative effects of benzodiazepines after sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures
  • Management of benzodiazepine overdose
  • Reversal of conscious sedation induced with benzodiazepines (pediatric patients)

How The Drug Works

  • Blocks benzodiazepine receptors at GABA-A ligand-gated chloride channel complex, preventing benzodiazepines from binding there

How Long Until It Works

  • Onset of action 1–2 minutes; peak effect 6–10 minutes

If It Works

  • Reverses sedation and psychomotor retardation rapidly, but may not restore memory completely
  • Patients treated for benzodiazepine overdose may experience CNS excitation
  • Patients who receive flumazenil to reverse benzodiazepine effects should be monitored for up to 2 hours for resedation, respiratory depression, or other lingering benzodiazepine effects
  • Flumazenil has not been shown to treat hypoventilation due to benzodiazepine treatment

If It Doesn’t Work

  • Sedation is most likely not due to a benzodiazepine, and treatment with flumazenil should be discontinued and other causes of sedation investigated

Best Augmenting Combos for Partial Response or Treatment-Resistance

  • None – flumazenil is basically used as a monotherapy antidote to reverse the actions of benzodiazepines

Tests

  • None for healthy individuals
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$225
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us